146 related articles for article (PubMed ID: 26218541)
1. In vitro evaluation of suspoemulsions for in situ-forming polymeric microspheres and controlled release of progesterone.
Turino LN; Mariano RN; Mengatto LN; Luna JA
J Microencapsul; 2015; 32(6):538-46. PubMed ID: 26218541
[TBL] [Abstract][Full Text] [Related]
2. Development of a novel formulation containing poly(d,l-lactide-co-glycolide) microspheres dispersed in PLGA-PEG-PLGA gel for sustained delivery of ganciclovir.
Duvvuri S; Janoria KG; Mitra AK
J Control Release; 2005 Nov; 108(2-3):282-93. PubMed ID: 16229919
[TBL] [Abstract][Full Text] [Related]
3. Effect of various additives and polymers on lysozyme release from PLGA microspheres prepared by an s/o/w emulsion technique.
Paillard-Giteau A; Tran VT; Thomas O; Garric X; Coudane J; Marchal S; Chourpa I; Benoît JP; Montero-Menei CN; Venier-Julienne MC
Eur J Pharm Biopharm; 2010 Jun; 75(2):128-36. PubMed ID: 20226857
[TBL] [Abstract][Full Text] [Related]
4. Controlled delivery of ganciclovir to the retina with drug-loaded Poly(d,L-lactide-co-glycolide) (PLGA) microspheres dispersed in PLGA-PEG-PLGA Gel: a novel intravitreal delivery system for the treatment of cytomegalovirus retinitis.
Duvvuri S; Janoria KG; Pal D; Mitra AK
J Ocul Pharmacol Ther; 2007 Jun; 23(3):264-74. PubMed ID: 17593010
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin loaded microspheres prepared from biodegradable LPLG-PEO-LPLG triblock copolymers: protein stabilization and in-vitro release properties.
Morlock M; Kissel T; Li YX; Koll H; Winter G
J Control Release; 1998 Dec; 56(1-3):105-15. PubMed ID: 9801434
[TBL] [Abstract][Full Text] [Related]
6. Naltrexone-loaded poly[La-(Glc-Leu)] polymeric microspheres for the treatment of alcohol dependence: in vitro characterization and in vivo biocompatibility assessment.
Pagar KP; Vavia PR
Pharm Dev Technol; 2014 Jun; 19(4):385-94. PubMed ID: 23590187
[TBL] [Abstract][Full Text] [Related]
7. Pluronic F127 gel effectively controls the burst release of drug from PLGA microspheres.
Wang Y; Gao JQ; Chen HL; Zheng CH; Liang WQ
Pharmazie; 2006 Apr; 61(4):367-8. PubMed ID: 16649559
[TBL] [Abstract][Full Text] [Related]
8. Iodo-2'-deoxyuridine (IUdR) and 125IUdR loaded biodegradable microspheres for controlled delivery to the brain.
Reza MS; Whateley TL
J Microencapsul; 1998; 15(6):789-801. PubMed ID: 9818956
[TBL] [Abstract][Full Text] [Related]
9. Water-soluble betamethasone-loaded poly(lactide-co-glycolide) hollow microparticles as a sustained release dosage form.
Chaw CS; Yang YY; Lim IJ; Phan TT
J Microencapsul; 2003; 20(3):349-59. PubMed ID: 12881115
[TBL] [Abstract][Full Text] [Related]
10. Effect of particle size, polydispersity and polymer degradation on progesterone release from PLGA microparticles: Experimental and mathematical modeling.
Busatto C; Pesoa J; Helbling I; Luna J; Estenoz D
Int J Pharm; 2018 Jan; 536(1):360-369. PubMed ID: 29217474
[TBL] [Abstract][Full Text] [Related]
11. Effect of mean diameter and polydispersity of PLG microspheres on drug release: experiment and theory.
Berchane NS; Carson KH; Rice-Ficht AC; Andrews MJ
Int J Pharm; 2007 Jun; 337(1-2):118-26. PubMed ID: 17289316
[TBL] [Abstract][Full Text] [Related]
12. Formulation and in vitro characterization of inhalable rifampicin-loaded PLGA microspheres for sustained lung delivery.
Doan TV; Couet W; Olivier JC
Int J Pharm; 2011 Jul; 414(1-2):112-7. PubMed ID: 21596123
[TBL] [Abstract][Full Text] [Related]
13. Preparation of preformed porous PLGA microparticles and antisense oligonucleotides loading.
Ahmed AR; Bodmeier R
Eur J Pharm Biopharm; 2009 Feb; 71(2):264-70. PubMed ID: 18840521
[TBL] [Abstract][Full Text] [Related]
14. Lappaconitine-loaded microspheres for parenteral sustained release: effects of formulation variables and in vitro characterization.
Xu H; Zhong H; Liu M; Xu C; Gao Y
Pharmazie; 2011 Sep; 66(9):654-61. PubMed ID: 22026119
[TBL] [Abstract][Full Text] [Related]
15. A novel in situ forming drug delivery system for controlled parenteral drug delivery.
Kranz H; Bodmeier R
Int J Pharm; 2007 Mar; 332(1-2):107-14. PubMed ID: 17084049
[TBL] [Abstract][Full Text] [Related]
16. Investigation of Fragment Antibody Stability and Its Release Mechanism from Poly(Lactide-co-Glycolide)-Triacetin Depots for Sustained-Release Applications.
Chang DP; Garripelli VK; Rea J; Kelley R; Rajagopal K
J Pharm Sci; 2015 Oct; 104(10):3404-17. PubMed ID: 26099467
[TBL] [Abstract][Full Text] [Related]
17. Rupture and drug release characteristics of multi-reservoir type microspheres with poly(dl-lactide-co-glycolide) and poly(dl-lactide).
Matsumoto A; Matsukawa Y; Horikiri Y; Suzuki T
Int J Pharm; 2006 Dec; 327(1-2):110-6. PubMed ID: 16971073
[TBL] [Abstract][Full Text] [Related]
18. A novel sustained-release formulation of recombinant human growth hormone and its pharmacokinetic, pharmacodynamic and safety profiles.
Wei Y; Wang Y; Kang A; Wang W; Ho SV; Gao J; Ma G; Su Z
Mol Pharm; 2012 Jul; 9(7):2039-48. PubMed ID: 22663348
[TBL] [Abstract][Full Text] [Related]
19. PLGA in situ implants formed by phase inversion: critical physicochemical parameters to modulate drug release.
Parent M; Nouvel C; Koerber M; Sapin A; Maincent P; Boudier A
J Control Release; 2013 Nov; 172(1):292-304. PubMed ID: 24001947
[TBL] [Abstract][Full Text] [Related]
20. PLGA-based drug delivery systems: importance of the type of drug and device geometry.
Klose D; Siepmann F; Elkharraz K; Siepmann J
Int J Pharm; 2008 Apr; 354(1-2):95-103. PubMed ID: 18055140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
